Equities research analysts forecast that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) will report ($0.66) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings. Corvus Pharmaceuticals posted earnings of ($0.55) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 20%. The firm is scheduled to report its next quarterly earnings results on Friday, March 9th.

On average, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($2.82) per share for the current fiscal year, with EPS estimates ranging from ($2.84) to ($2.80). For the next year, analysts forecast that the firm will report earnings of ($3.23) per share, with EPS estimates ranging from ($3.28) to ($3.18). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19.

Several research analysts have recently issued reports on CRVS shares. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Monday, August 28th. Credit Suisse Group raised shares of Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 target price on the stock in a research note on Wednesday, August 23rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $20.25.

Shares of Corvus Pharmaceuticals (NASDAQ CRVS) traded down $0.31 during trading hours on Thursday, reaching $10.69. 49,600 shares of the company’s stock were exchanged, compared to its average volume of 106,371. Corvus Pharmaceuticals has a 12-month low of $8.27 and a 12-month high of $22.14.

In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller bought 10,000 shares of Corvus Pharmaceuticals stock in a transaction dated Monday, November 20th. The shares were bought at an average price of $10.79 per share, with a total value of $107,900.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 46.40% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Jennison Associates LLC raised its position in shares of Corvus Pharmaceuticals by 87.4% in the 2nd quarter. Jennison Associates LLC now owns 1,019,013 shares of the company’s stock valued at $12,330,000 after acquiring an additional 475,164 shares during the period. EcoR1 Capital LLC acquired a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter valued at approximately $9,741,000. Vanguard Group Inc. raised its position in shares of Corvus Pharmaceuticals by 37.1% in the 2nd quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock valued at $4,520,000 after acquiring an additional 101,013 shares during the period. JPMorgan Chase & Co. raised its position in shares of Corvus Pharmaceuticals by 116.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 332,634 shares of the company’s stock valued at $4,025,000 after acquiring an additional 178,658 shares during the period. Finally, Northern Trust Corp raised its position in shares of Corvus Pharmaceuticals by 97.6% in the 2nd quarter. Northern Trust Corp now owns 86,525 shares of the company’s stock valued at $1,047,000 after acquiring an additional 42,739 shares during the period. 83.47% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/07/brokerages-expect-corvus-pharmaceuticals-inc-crvs-will-post-earnings-of-0-66-per-share.html.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.